Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001209191-22-015794 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-03 | 2022-03-01+ | ACRS | Walker Neal | Pres, CEO, Dir | M - OptEx | — | +132.7K | 1.35M | +11% | — |
| DM | 2022-03-03 | 2022-03-01 | ACRS | Walker Neal | Pres, CEO, Dir | A - Grant | $0.00 | +432.1K | 336.1K | New | $0 |
| DM | 2022-03-03 | 2022-03-01+ | ACRS | Walker Neal | Pres, CEO, Dir | M - OptEx | $0.00 | -132.7K | 36.5K | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-02 | M | A | 18,254 | — | 1,372,066 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Common | Common Stock | 2022-03-01 | M | A | 96,150 | — | 1,335,537 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 3 | Common | Common Stock | 2022-03-01 | M | A | 18,275 | — | 1,353,812 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 4 | Derivative | Restricted stock units | 2022-03-01 | A | A | 96,000 | $0.00 | 96,000 | D | — · — to — | 96,000 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2022-03-01 | A | A | 336,100 | $0.00 | 336,100 | D | $14.94 · — to 2032-02-29 | 336,100 Common Stock | (F2) Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. |
| 6 | Derivative | Restricted stock units | 2022-03-01 | M | D | 96,150 | $0.00 | 96,150 | D | — · — to — | 96,150 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F4) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. |
| 7 | Derivative | Restricted stock units | 2022-03-01 | M | D | 18,275 | $0.00 | 54,825 | D | — · — to — | 18,275 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F5) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. |
| 8 | Derivative | Restricted stock units | 2022-03-02 | M | D | 18,254 | $0.00 | 36,508 | D | — · — to — | 18,254 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F6) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. |